Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New ear scanner could slash unnecessary antibiotics in kids

NCT ID NCT06285812

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device called OtoSight that helps doctors see inside a child's ear more clearly. The goal is to see if using it leads to fewer unnecessary antibiotic prescriptions, better outcomes, and lower costs. About 700 children aged 6 months to 17 years with ear pain are taking part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 700 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Any pediatric patient between 6 months and 17 years of age scheduled for an office visit with ear-related complaints, deemed suitable for otoscopy assessment.

Ages

6 months to 17 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For the Prospective Subjects Inclusion Criteria: * Pediatric subjects between 6 months and 17 years of age * Pediatric subjects presenting for an office visit with ear-related pain (otalgia)/otic complaints/earache indicative of potential Otitis Media with Effusion (OME) or Acute Otitis Media (AOM) * Pediatric subjects where otoscopy would traditionally be indicated * Pediatric subjects whose parents or legally authorized representative (LAR) have signed an informed consent Exclusion Criteria: * The parent or guardian who attends visits does not speak the same language as their physician * Pediatric subjects enrolled in another clinical trial * Pediatric subjects with: * Signs of severe chronic illness (e.g., immunodeficiency, congenital heart disease, encephalopathy, pulmonary disease other than asthma, and disorder of the ear, nose and throat) or any clinically significant illness or condition that, in the opinion of the investigator, would prohibit the subject from participating in the trial * Anatomical conditions that would affect their ability to undergo an otoscopy. For the Retrospective Case Match Controls Inclusion Criteria: * Pediatric subjects between 6 months and 17 years of age (\< 18 years old). * Index visit took place 11 - 25 months prior to the Treatment match's Baseline Visit. * Index visit was for an ear-related chief complaint. * An otoscopic exam was completed at index visit. * Subjects have a follow up visits (telehealth included) in the time period between the index visit and firstTreatment subject's enrollment date.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Otitis media acute are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Abba Medical Group LLC

    Miami, Florida, 33175, United States

  • AdventHealth Children's Research

    Orlando, Florida, 32802, United States

  • Carolina ENT

    Orangeburg, South Carolina, 29118, United States

  • Children's National Hospital

    Washington D.C., District of Columbia, 20010, United States

  • Cyn3rgy Research

    Gresham, Oregon, 97030, United States

  • HealthStar Physicians

    Morristown, Tennessee, 37813, United States

  • Trillim Health

    Rochester, New York, 14620, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.